Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.12
  • Today's Change0.61 / 3.48%
  • Shares traded4.58m
  • 1 Year change+51.76%
  • Beta2.2436
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

  • Revenue in USD (TTM)642.82m
  • Net income in USD-43.54m
  • Incorporated2012
  • Employees1.31k
  • Location
    10X Genomics Inc6230 Stoneridge Mall RoadPLEASANTON 94588United StatesUSA
  • Phone+1 (925) 401-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.10xgenomics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TXG:NSQ since
announced
Transaction
value
Scale Biosciences IncAnnounced07 Aug 202507 Aug 2025Announced43.13%30.00m
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Quidelortho Corp2.73bn-1.13bn1.60bn6.60k--0.8341--0.5867-16.66-16.6640.2728.270.44782.627.46---18.56-6.45-22.13-7.3946.6753.89-41.45-14.400.90020.67570.5798---1.8910.4444.84------
AtriCure Inc518.31m-28.77m1.62bn1.30k--3.41--3.13-0.608-0.60810.909.590.8291.688.79398,696.20-4.60-3.84-5.24-4.2574.8774.53-5.55-7.132.85-17.960.1252--16.5515.05-46.85--14.00--
Omnicell Inc1.18bn2.05m1.64bn3.60k844.321.3320.011.380.04320.043225.7027.450.57867.195.01--0.10020.73310.13570.976742.4944.800.17321.321.22--0.1198--6.535.84-83.62-42.341.93--
AxoGen Inc214.71m-2.10m1.67bn451.00--12.69343.247.76-0.0486-0.04864.562.621.051.557.75476,073.20-1.03-11.36-1.17-13.0574.7678.42-0.9767-15.372.640.64930.2852--17.8111.9154.12---2.84--
Inspire Medical Systems Inc911.98m145.42m1.71bn1.25k12.022.1910.711.874.974.9730.7527.331.061.188.57--16.953.0919.003.4885.3984.8315.953.054.56------13.6051.21171.77------
Artivion Inc422.65m-9.12m1.75bn1.60k--3.95126.384.14-0.242-0.2429.489.260.5091.725.16264,153.80-1.10-2.47-1.29-2.6664.5065.02-2.16-5.892.881.290.3324--9.757.0656.37--6.75--
Heartflow Inc-100.00bn-100.00bn1.76bn699.00--6.77----------3.05----------------------------0.00--44.32--22.04------
UFP Technologies Inc597.95m67.12m1.90bn4.15k28.544.6922.063.178.618.6176.7152.370.92614.896.86144,223.8010.4010.1211.8711.5328.5127.0711.2310.641.368.390.26570.0026.0820.5231.2924.4610.82--
Alphatec Holdings Inc728.02m-154.96m1.98bn867.00--173.41--2.73-1.05-1.054.910.23510.94971.287.90839,700.10-20.21-27.43-26.81-34.6969.2366.99-21.29-39.401.24-1.860.941--26.8140.0713.14--48.19--
LeMaitre Vascular Inc240.87m53.34m1.99bn651.0038.415.2531.258.262.282.2810.3516.710.4941.037.45369,993.8010.949.0911.699.8970.9766.2422.1416.6411.45--0.307738.3813.6313.4046.2819.6813.1115.91
Establishment Labs Holdings Inc190.97m-82.98m2.17bn1.02k--132.47--11.35-2.84-2.846.530.56320.61450.7692.75187,596.30-26.70-31.53-33.25-39.3268.7465.46-43.45-45.092.10-1.720.9377--0.529213.14-7.76--17.33--
10X Genomics Inc642.82m-43.54m2.31bn1.31k--2.91--3.60-0.3496-0.34965.156.240.65592.859.53---4.44-14.35-5.16-16.4369.1172.26-6.77-24.504.09------5.2516.5576.16------
Neogen Corp880.32m-602.74m2.38bn2.97k--1.13--2.70-2.78-2.784.059.670.23752.635.95296,005.00-16.26-7.73-16.94-8.0645.9848.10-68.47-27.912.80-0.21090.2737---3.2016.43-11,491.59--34.18--
DENTSPLY SIRONA Inc3.62bn-882.00m2.58bn14.00k--1.75--0.7131-4.43-4.4318.187.410.59032.725.47258,857.10-14.35-4.06-18.88-4.8351.1053.14-24.31-8.590.98659.680.6184---4.34-1.17-589.39--7.9111.28
Haemonetics Corp1.32bn175.44m2.68bn3.02k15.872.979.322.043.643.6427.4019.460.5251.586.47436,081.706.995.418.306.5559.3253.2013.319.181.1512.690.57330.003.956.6042.6416.994.37--
Integer Holdings Corp1.83bn87.20m3.01bn11.00k35.841.7214.251.642.402.3951.7649.830.55785.044.83166,461.302.663.282.843.5427.1526.704.766.382.455.230.41120.0010.356.4135.805.8216.99--
Data as of Feb 13 2026. Currency figures normalised to 10X Genomics Inc's reporting currency: US Dollar USD

Institutional shareholders

57.31%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Dec 202512.67m10.88%
The Vanguard Group, Inc.as of 31 Dec 202512.10m10.39%
BlackRock Fund Advisorsas of 31 Dec 20258.29m7.12%
Fidelity Management & Research Co. LLCas of 30 Sep 20257.21m6.19%
Amova Asset Management Co., Ltd.as of 31 Dec 20255.49m4.72%
Amova Asset Management Americas, Inc.as of 31 Dec 20255.49m4.71%
Millennium Management LLCas of 30 Sep 20255.44m4.67%
Wellington Management Co. LLPas of 30 Sep 20253.78m3.25%
Quantinno Capital Management LPas of 30 Sep 20253.49m3.00%
Geode Capital Management LLCas of 31 Dec 20252.79m2.40%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.